The evaluation of an individualised dosing strategy derived from population PK modelling and simulation

Background: Recently published enoxaparin dosing guidelines for obese and renally impaired patients are purported to increase the probability of achieving and maintaining anti-Xa (aXa) concentrations within the therapeutic range (TR) of 500-1000 IU/L. Exposure-response data indicate that concentrations greater than the TR increase the risk of bleeding, while concentrations less than the TR increase mortality. Aim: To […]